Core Viewpoint - The company, CanSino, has positioned its product, Manhaixin, as the only approved quadrivalent meningococcal vaccine in China, targeting the mid-to-high-end infant vaccine market, with increasing market acceptance and sales growth indicating a strong demand for high-quality infant vaccines [1] Group 1: Product Development and Market Expansion - Manhaixin has seen a steady increase in sales revenue, confirming the domestic market's demand for premium infant vaccines [1] - The company has submitted a supplementary application to expand the age range for Manhaixin from infants to children aged 3 months to 6 years, and plans to pursue further age expansion for adolescents and adults aged 7 to 59 years [1] - Manhaixin has been launched in Indonesia as of September 2025, marking the start of its sales in the local market, with ongoing efforts to expand into other target countries and regions [1] Group 2: Financial Performance - For the third quarter of 2025, the company reported a revenue of approximately 693 million yuan, representing a year-on-year growth of 22% [1] - The sales revenue from meningococcal products reached about 662 million yuan in the first three quarters, reflecting a 28% increase compared to the same period last year [1] Group 3: Incentives and Growth Targets - The company has announced a new equity incentive plan, setting revenue growth targets for 2025, indicating a commitment to achieving these objectives [1]

Core Viewpoint - The company, CanSino, has successfully positioned its product, Manhaixin®, as the only approved quadrivalent meningococcal conjugate vaccine in China, targeting the mid-to-high-end infant vaccine market, with increasing market acceptance and sales growth indicating a strong demand for high-quality vaccines in the domestic market [1] Group 1: Product Development and Market Expansion - Manhaixin® has seen steady sales growth, confirming the domestic market's demand for premium infant vaccines [1] - The company has submitted a supplementary application to expand the age indication of Manhaixin® to children aged 3 months to 6 years and plans to pursue further age expansion for adolescents and adults (ages 7 to 59) [1] - Manhaixin® was launched in Indonesia in September 2025, marking the start of its sales in the local market, with ongoing efforts to expand into other target countries and regions [1] Group 2: Financial Performance - For the third quarter of 2025, the company reported revenue of approximately 693 million yuan, representing a year-on-year increase of 22% [1] - The sales revenue from meningococcal products for the first three quarters reached approximately 662 million yuan, a 28% increase compared to the same period last year [1] Group 3: Incentives and Growth Targets - The company has announced a new equity incentive plan, setting revenue growth targets for 2025, indicating a commitment to achieving these objectives [1]